MaaT Pharma Completes a Capital Increase of €13 Million with Historical Shareholders and Announces 2024…
MaaT PharmaMarch 27, 2025
MaaT Pharma Receives Positive Opinion from EMA Pediatric Committee on the Pediatric Investigation Plan for…
MaaT PharmaMarch 11, 2025
MaaT Pharma Announces Positive Second DSMB Review of Ongoing Phase 2b Clinical Trial Evaluating MaaT033…
MaaT PharmaJanuary 21, 2025
MaaT Pharma Announces Positive Topline Results from the Pivotal Phase 3 ARES Study Evaluating MaaT013…
MaaT PharmaJanuary 8, 2025
MaaT Pharma: Monthly Information Regarding the Total Number of Voting Rights and Shares Comprising the…
MaaT PharmaJanuary 7, 2025
MaaT Pharma Presented Positive Updated Data on MaaT013 in the Early Access Program at ASH…
MaaT PharmaDecember 10, 2024
MaaT Pharma Announces First U.S. Patient Treated at City of Hope Under Single Patient Expanded…
MaaT PharmaDecember 5, 2024
MaaT Pharma Announces Positive Phase 1b Results, Meeting Primary Endpoint in the Evaluation of MaaT033…
MaaT PharmaNovember 26, 2024
MaaT Pharma to Present Updates from Early Access Program at the 2024 ASH Annual Meeting…
MaaT PharmaNovember 7, 2024
